抄録
Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 520-528 |
| ページ数 | 9 |
| ジャーナル | Breast Cancer |
| 巻 | 22 |
| 発行部数 | 5 |
| DOI | |
| 出版物ステータス | 出版済み - 9 7 2015 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Radiology Nuclear Medicine and imaging
- Pharmacology (medical)
これを引用
Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer. / Hisamatsu, Yuichi; Tokunaga, Eriko; Yamashita, Nami; Akiyoshi, Sayuri; Okada, Satoko; Nakashima, Yuichiro; Taketani, Kenji; Aishima, Shinichi; Oda, Yoshinao; Morita, Masaru; Maehara, Yoshihiko.
：: Breast Cancer, 巻 22, 番号 5, 07.09.2015, p. 520-528.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer
AU - Hisamatsu, Yuichi
AU - Tokunaga, Eriko
AU - Yamashita, Nami
AU - Akiyoshi, Sayuri
AU - Okada, Satoko
AU - Nakashima, Yuichiro
AU - Taketani, Kenji
AU - Aishima, Shinichi
AU - Oda, Yoshinao
AU - Morita, Masaru
AU - Maehara, Yoshihiko
PY - 2015/9/7
Y1 - 2015/9/7
N2 - Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.
AB - Background: Determining the indications for adjuvant chemotherapy (CT) in patients with hormone receptor (HR)-positive/HER2-negative breast cancer are difficult. The transcription factors GATA-binding protein 3 (GATA-3) and Forkhead-box protein A1 (FOXA1) are crucial for the hormone responsive phenotype of breast cancer. This study evaluated whether the expression of GATA-3 and FOXA1 is a prognostic and predictive marker of outcomes in patients with HR-positive/HER2-negative breast cancer. Methods: The expression of GATA-3 and FOXA1 was analyzed immunohistochemically in 214 patients with invasive breast cancer to evaluate the association with the clinicopathological features and the prognosis. Results: GATA-3 expression was positively correlated with FOXA1 expression (P < 0.0001). Both GATA-3 and FOXA1 were positively correlated with ER (P < 0.0001 each) and PR expression (P = 0.0001 and P = 0.0009, respectively), and inversely correlated with nuclear grade (P = 0.0002 and P = 0.0018, respectively) and Ki67 index (P = 0.0052 and P = 0.0049, respectively). Expression of GATA-3 and FOXA1 was associated with better prognosis. FOXA1 was an independent favorable prognostic marker in HR-positive/HER2-negative breast cancer. Disease-free survival rates were similar in patients with HR-positive/HER2-negative breast cancer and high FOXA1 expression given adjuvant hormone therapy (HT) alone and those given CT plus HT. Conclusion: GATA-3 and FOXA1 are associated with a less aggressive phenotype and a better prognosis in patients with HR-positive/HER2-negative breast cancer. FOXA1 may be useful in identifying those patients who may not require adjuvant CT.
UR - http://www.scopus.com/inward/record.url?scp=84940954066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940954066&partnerID=8YFLogxK
U2 - 10.1007/s12282-013-0515-x
DO - 10.1007/s12282-013-0515-x
M3 - Article
C2 - 24415069
AN - SCOPUS:84940954066
VL - 22
SP - 520
EP - 528
JO - Breast Cancer
JF - Breast Cancer
SN - 1340-6868
IS - 5
ER -